MC4R is a core receptor in the hypothalamic melanocortin energy-homeostasis pathway and directly connects Leptin–POMC–α-MSH signaling with food intake, hunger, and energy expenditure. Unlike conventional weight-loss drugs, the distinctive value of MC4R agonism lies in restoring impaired satiety signaling in specific genetic defects or hypothalamic pathway abnormalities. Therefore, MC4R is a target with relatively strong mechanistic and clinical validation in precision obesity treatment.

Keywords: MC4R; POMC; α-MSH; AgRP; Setmelanotide; genetic obesity; hypothalamic obesity

1 Functional Positioning of MC4R in Energy Homeostasis

1.1 Receptor Characteristics of MC4R

Melanocortin 4 receptor (MC4R) is encoded by the MC4R gene and belongs to the Class A G protein-coupled receptor family. It is mainly expressed in the central nervous system and has important functions in the hypothalamic paraventricular nucleus (PVN) and other regions involved in feeding and autonomic regulation. MC4R lies downstream of multiple nutrient, fat-storage, and neuropeptide signals, and its functional state directly affects hunger, Meal Size, Energy Intake, and some autonomic and energy-expenditure responses.

1.2 POMC–α-MSH–MC4R Pathway

(1) POMC Neurons Generate Melanocortin Signals

POMC neurons in the hypothalamic arcuate nucleus receive inputs related to Leptin, Insulin, and nutritional status. POMC is processed by systems including PCSK1 and PCSK2 to generate multiple active peptides, among which α-MSH is an important endogenous agonist ligand of MC4R. After release, α-MSH activates downstream MC4R neurons, converting the signal of “sufficient energy stores” into suppression of food intake.

(2) MC4R Generates Downstream Satiety Output

MC4R activation can reduce Food Intake and enhance Satiation while also participating in regulation of Energy Expenditure through autonomic and neuroendocrine networks. MC4R is therefore not simply an “appetite receptor” but a core output node in the melanocortin energy-homeostasis network.

1.3 AgRP-Mediated Opposing Regulation

Agouti-related peptide (AgRP) neurons and POMC neurons form oppositely directed feeding-regulatory systems. During energy deficiency, AgRP neuronal activity increases and releases AgRP, NPY, and GABA. Among these, AgRP can reduce MC4R activity, weakening satiety output and promoting food intake. MC4R therefore lies at the center of a dynamic balance between α-MSH agonism and AgRP-mediated inhibition.

2 MC4R Signal Transduction Mechanisms

2.1 Gs–cAMP Signaling

After activation, MC4R mainly couples to Gs proteins, promotes Adenylate Cyclase activation, and increases intracellular cAMP, further regulating PKA and other cAMP-related effector systems. This pathway is a classical functional readout for evaluating MC4R ligand activity. Receptor agonists usually produce dose-dependent increases in cAMP, whereas loss-of-function receptor variants may show a rightward shift in EC₅₀, reduced Emax, or complete absence of response.

2.2 Neuronal Excitation and Feeding Output

MC4R signaling ultimately needs to be converted into electrical activity and network output of specific neurons. Activation of MC4R neurons in regions such as the PVN can suppress food intake and influence gastrointestinal function, sympathetic activity, and energy metabolism through the brainstem, autonomic nervous system, and other downstream nuclei. Different MC4R neuronal populations do not perform completely identical functions, so the overall phenotype generated by receptor agonism results from the combined actions of multiple central neural circuits.

2.3 Receptor Expression, Trafficking, and Functional Variants

MC4R mutations do not simply fall into “functional” and “nonfunctional” categories. Some variants reduce receptor membrane expression, some affect ligand binding, and others mainly affect G-protein coupling or signaling duration. MC4R can also localize to neuronal primary cilia, and correct trafficking is important for physiological function in some neurons. Therefore, genetic obesity research needs to distinguish receptor-expression defects, cellular-trafficking defects, and signaling-coupling defects.

3 MC4R Pathway Abnormalities and Obesity

3.1 POMC, PCSK1, and LEPR Defects

(1) POMC Deficiency

POMC deficiency can reduce production of melanocortin peptides such as α-MSH, resulting in insufficient endogenous agonist input to MC4R. Its core metabolic consequences are severe Hyperphagia and early-onset obesity, while MC4R itself may remain functional. Therefore, direct pharmacological activation of MC4R has a clear downstream compensation logic.

(2) PCSK1 Deficiency

PCSK1 participates in processing multiple prohormones, and abnormal POMC processing can lead to insufficient formation of active melanocortin peptides. Although PCSK1 deficiency also involves other endocrine and gastrointestinal phenotypes, insufficient formation of upstream MC4R agonist ligands is an important component of its obesity mechanism.

(3) LEPR Deficiency

Loss of Leptin receptor (LEPR) function prevents adipose tissue energy-storage signals from being normally transmitted to the hypothalamus, reducing POMC neuronal activation while enhancing AgRP-related feeding drive. Because the abnormality lies upstream of MC4R, direct activation of MC4R can bypass part of the upstream signaling defect when MC4R function remains intact.

3.2 Functional Defects in MC4R Itself

Loss-of-function variants in MC4R are an important cause of monogenic early-onset obesity and can lead to pronounced Hyperphagia and persistent weight gain. A particularly important distinction is that MC4R being a therapeutic target does not mean that all MC4R defects are suitable for treatment with MC4R agonists. If a variant causes complete failure of receptor expression, ligand binding, or effective signaling, increasing exogenous agonist exposure is unlikely to restore function. Only variants retaining a certain degree of receptor function may have pharmacological recovery potential.

3.3 BBS and Cilia-Related MC4R Pathways

Bardet-Biedl syndrome (BBS) involves abnormalities in primary cilia and protein trafficking, while neuronal ciliary localization of MC4R is associated with normal energy homeostasis. Obesity in BBS cannot be simply attributed to a single MC4R gene defect, but abnormalities in the melanocortin pathway and ciliary signaling make MC4R a therapeutically valuable downstream node. This also indicates that precision obesity includes not only classical single-gene defects involving POMC, PCSK1, and LEPR.

Table 1 Levels of Action of Different MC4R Pathway Abnormalities

4 MC4R and Precision Obesity Treatment

4.1 Core Logic of Precision Treatment

MC4R-targeted drugs are not selected simply according to BMI. Instead, it is necessary to determine whether obesity involves a defined melanocortin-pathway abnormality and whether MC4R itself retains sufficient function. For upstream defects involving LEPR, POMC, or PCSK1, direct MC4R activation effectively bypasses the impaired step. For severe loss of function in MC4R itself, the residual function of the specific variant needs to be evaluated first.

4.2 Hyperphagia as an Important Therapeutic Phenotype

Persistent Hyperphagia is one of the most prominent manifestations of MC4R pathway defects. The primary problem is not ordinary dietary preference but insufficient physiological satiety signaling, resulting in persistent hunger and abnormally increased Meal Size and Energy Intake. Therefore, key clinical phenotypes for MC4R treatment include not only Body Weight and BMI but also Hunger Score, Hyperphagia, and changes in feeding behavior.

4.3 From Genetic Diagnosis to Functional Stratification

Precision treatment should not stop at “identifying a genetic variant.” Different variants within the same MC4R gene can separately affect membrane expression, ligand binding, Gs-cAMP signaling, and receptor trafficking, and their pathogenicity and degree of pharmacological recoverability are not identical. Combining genetic testing with in vitro functional experiments can further distinguish Variants of Uncertain Significance from true loss-of-function variants and provide a basis for determining whether MC4R agonists have a mechanistic basis for action.

5 Acquired Hypothalamic Obesity

5.1 Hypothalamic Injury and Disruption of Energy Homeostasis

Acquired hypothalamic obesity can occur after hypothalamic tumors, surgery, radiotherapy, or other injuries. After damage to hypothalamic networks, multiple regulatory mechanisms involving Leptin, Insulin, POMC, and autonomic signaling may become abnormal simultaneously, resulting in persistent hunger, reduced energy expenditure, and rapid weight gain. This type of obesity differs from ordinary lifestyle-related obesity, and caloric restriction alone is often insufficient to correct central disruption of energy homeostasis.

5.2 MC4R as a Downstream Intervention Node

As long as downstream MC4R neurons and receptors retain sufficient function, direct MC4R agonism may bypass some impaired upstream neural inputs and restore stronger satiety and food-intake-suppressing output. This mechanism extends the therapeutic scope of MC4R from clearly defined monogenic obesity to some forms of acquired hypothalamic pathway injury and demonstrates its precision-treatment value based on “pathway-based stratification” rather than simply “gene-based stratification.”

5.3 Outcome Evaluation

Studies of hypothalamic obesity should not observe Body Weight alone but should also record BMI/BMI Z-score, Hunger Score, Food Intake, and body composition. Some patients have low Energy Expenditure, so the magnitude of weight loss needs to be interpreted together with basal energy metabolism and the extent of hypothalamic injury rather than being directly compared with conventional obesity-drug trials.

6 Pharmacological Characteristics of Setmelanotide

6.1 MC4R Agonist

Setmelanotide is a representative peptide MC4R agonist used for obesity associated with MC4R-pathway abnormalities. It can directly activate MC4R and enhance downstream melanocortin signaling. Its pharmacological core is not to increase Leptin or regenerate α-MSH but to provide direct agonist input to still-functional MC4R when upstream signaling is deficient.

6.2 Restoration of Satiety Signaling

After activating MC4R, Setmelanotide enhances central Satiation and reduces persistent Hunger and Hyperphagia, thereby decreasing abnormal energy intake. For upstream defects such as POMC, PCSK1, or LEPR abnormalities, this action has a clear “signal bypass” property: the pathological defect remains present, but the drug directly restores part of the melanocortin output from downstream.

6.3 Applicable Populations Depend on Pathway Location

(1) Upstream Defects

POMC, PCSK1, LEPR, and some other melanocortin-pathway abnormalities preserve functional MC4R and therefore provide a relatively clear pharmacological basis for MC4R agonism.

(2) MC4R Variants

If an MC4R variant retains membrane expression and partial signaling function, increasing agonist intensity may produce a certain degree of functional recovery. If the receptor is completely inactive, Setmelanotide cannot simply bypass the defect. Therefore, when the MC4R gene itself is abnormal, functional testing is more important than merely determining whether a variant is present.

(3) Hypothalamic Obesity

Acquired hypothalamic obesity is not a single-gene disease. The rationale for Setmelanotide use is based on the possibility that some patients retain downstream MC4R networks that can be directly activated to enhance suppression of food intake.

6.4 Pharmacological Boundaries and Safety

MC4R belongs to the Melanocortin receptor family, and activity of a drug at other Melanocortin receptors may produce additional phenotypes, such as skin-pigmentation changes related to MC1R. Central MC4R action also requires attention to safety indicators such as nausea, injection-site reactions, and neuropsychiatric status. Therefore, the core value of Setmelanotide is not as a broad-spectrum potent appetite suppressant but in achieving a high degree of mechanistic matching in populations with appropriate pathway defects.

Table 2 Representative MC4R Ligands and Their Pharmacological Positioning

7 Differences Between MC4R and Conventional Weight-Loss Pathways

7.1 Differences From GLP-1R/GIPR

GLP-1R- and GIPR-related drugs mainly regulate feeding and metabolism through gastrointestinal hormone–pancreatic islet–central networks and are used broadly in conventional obesity and metabolic diseases. MC4R treatment, in contrast, depends more strongly on whether a defined melanocortin-pathway abnormality is present. Therefore, Setmelanotide is not a conventional alternative to Semaglutide or Tirzepatide; these drug classes address energy-intake dysregulation arising from different pathological bases.

7.2 Differences From the Amylin Receptor

The Amylin receptor mainly enhances meal-related Satiation and Meal Termination, whereas MC4R is more closely related to long-term central energy-homeostasis setting. Amylin signaling reflects current nutrient input, whereas MC4R integrates Leptin, POMC, AgRP, and long-term energy-storage status. Therefore, MC4R defects can produce persistent Hyperphagia rather than only insufficient satiety during individual meals.

7.3 Precision Obesity and Conventional Obesity

An important significance of MC4R pathway research is that it further divides “obesity” into distinct biological subtypes. In patients with defined genetic defects, ciliary abnormalities, or hypothalamic injury, the same BMI may correspond to completely different pathological mechanisms. The core of precision treatment is to identify the pathway location responsible for abnormal energy homeostasis rather than using the same receptor agonist for all patients with obesity.

8 Key Experiments in MC4R Research

8.1 MC4R Receptor Function

Cellular functional studies of MC4R can measure cAMP after stimulation with α-MSH, NDP-α-MSH, or Setmelanotide, establish a Concentration–Response curve, and compare EC₅₀ and Emax. When studying genetic variants, receptor membrane expression and total protein levels should also be examined simultaneously to distinguish “reduced receptor expression” from “normal expression with defective signaling.”

8.2 Functional Classification of Genetic Variants

(1) Ligand Binding and Membrane Expression

When a receptor cannot reach the cell membrane, normal pharmacological responses are difficult to obtain even if the coding sequence is present. Membrane-protein detection, cell-surface labeling, or imaging can assist in determining MC4R trafficking defects.

(2) Gs-cAMP Response

Comparing cAMP responses after α-MSH or Setmelanotide stimulation under conditions of similar membrane expression can determine whether a variant mainly affects ligand potency, maximal response, or G-protein coupling.

(3) Pharmacological Recoverability

Some MC4R variants may respond weakly to native α-MSH but retain a certain degree of response to potent agonists. Comparing EC₅₀ and Emax for α-MSH and Setmelanotide can help determine whether a specific variant retains residual pharmacological function rather than determining its functional status solely from sequence prediction.

8.3 Central Feeding Phenotypes

Animal studies can simultaneously record Food Intake, Meal Size, Body Weight, and Energy Expenditure and combine these with POMC/AgRP neuronal status, c-Fos, and responses in hypothalamic regions to determine whether MC4R activation is truly translated into changes in feeding networks. Precision obesity research particularly needs to link molecular receptor function with the Hyperphagia phenotype rather than observing only final changes in body weight.

9 MC4R-Related Research Products

9.1 MC4R Agonists, Antagonists, and Melanocortin Ligands

9.2 POMC–AgRP Feeding Network and Neural Responses

9.3 MC4R–cAMP/PKA–CREB Functional Validation

The key to MC4R precision treatment is not simply to enhance appetite suppression, but to identify the location of abnormalities within the melanocortin pathway and determine whether downstream MC4R remains functional. Upstream defects involving POMC, PCSK1, and LEPR, as well as some hypothalamic injuries, can restore satiety output through direct MC4R agonism, whereas severe loss of function in MC4R itself requires further functional stratification.

For more related articles, please see below:

[1] Exendin-4 and Alzheimer’s Disease

[2] Glucose measurement experiment

[3] A Detailed Guide to the Construction of Animal Models for Metabolic Diseases

[4] Linking Alzheimer’s Disease and Insulin Signaling

[5] Metformin

[6] Animal models of nutritional obesity